Drug Trial Radar · NCT03240809
An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects
Last checked: Nov 20, 2026Latest source record: Sep 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
2
Actual
Start
Jan 24, 2020
Primary completion
Dec 2028
Study completion Jun 2029
Sponsor
- Lead sponsor
- Bausch Health Americas, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 7, 2017
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects
Conditions
- Psoriasis
Interventions
BrodalumabBiological
140 mg SC dose
BrodalumabBiological
70 mg SC dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- maximum observed concentration (Cmax)Time frame: 29 Days
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Bausch Site 003
San Diego, California
Bausch Site 002
Miami, Florida
Bausch Site 004
Miami, Florida
Bausch Site 005
Henderson, Nevada
Bausch Site 001
Las Vegas, Nevada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.